“How long does Sculptra last?” is the question behind about 4,000 US searches a month, together with “Sculptra results”, “does Sculptra work” and “Sculptra timeline” (clickstream estimate, October 2026). The maker's answer is two years. This page reads the studies behind that answer, and a longer one that shows what happened after year 2, as of 14 October 2026. It is not advice about treatment; whether and how often anyone is treated is a decision for a qualified clinician. What Sculptra is and its full approval record are on our Sculptra explainer.
The claim, and where it comes from
Galderma's US Sculptra site says results can be seen “as early as 1 month after treatment” and last “up to 2 years”, and that 86% of trial participants had an improved jawline contour two years after treatment in the cheek region. Its footnotes cite two internal clinical study reports, coded 43USSA1812 and 43USSA1812EXT, and note that the “clinical study ended at 96 weeks (2 years)” (sculptrausa.com, read 14 October 2026). Those codes match two public registry entries: the cheek-wrinkle trial behind the 2023 approval (NCT04124692) and its open-label extension (NCT04595331). So “up to 2 years” describes where the follow-up stopped, not where the effect stopped.
When results appear
Sculptra is poly-L-lactic acid, and its effect is attributed to a tissue response that builds after the particles are placed, not to the volume of liquid injected; the liquid is absorbed within days. That is why every trial measures its main result months after the last session:
| Trial | Sessions | First main measurement | Main result |
|---|---|---|---|
| Nasolabial folds, 2009 approval (Narins 2010) | 1–4, three weeks apart | month 3 after the last session | better than a collagen implant from month 3 to month 13 |
| Cheek wrinkles, 2023 approval (NCT04124692) | up to 4, a month apart | month 7 | 66.2% responders at month 7, 71.6% at month 12, vs 38.6% and 26.1% untreated |
The cheek-trial figures are the share improving by at least one grade on the sponsor's cheek-wrinkle scale, set out in full on our Sculptra page.
Two years: the extension study
After the cheek trial ended at month 12, 111 participants entered a 12-month open-label extension, which posted its results to the registry. It reports two groups: one labelled “Sculptra Aesthetic”, treated in the extension (39 people), and one labelled “No Treatment”, followed with no additional treatment (72 people). The registry does not say in so many words which original arm each came from; the sizes match the pivotal trial's untreated arm (52) and treated arm (97) less those who did not continue, and the second group is the one that answers the duration question — people treated in the original trial and not retreated.
| Group, as labelled in the registry | Evaluable | Month 19 | Month 21 | Month 24 |
|---|---|---|---|---|
| No additional treatment (treated in the original trial) | 66 | 84.8% | 76.9% | 76.9% |
| Treated in the extension | 38 | 33.3% | 36.8% | 42.1% |
Responders here mean at least a one-grade improvement from the original baseline on both cheeks at once, judged live by a blinded evaluator. Read plainly, most people treated in the original trial were still rated improved two years after starting. Three cautions travel with that: the extension had no untreated comparison group, people who chose to continue may differ from those who left, and the sponsor designed and ran both studies. The extension recorded serious adverse events in 1 of 72 and 0 of 39 participants.
Five years: how the improvement faded
The longest record is Sculptra's five-year post-approval study, run by Galderma (NCT02425943). It enrolled 867 people from May 2015, gave a single treatment course for nasolabial folds and other facial wrinkles, and followed them for five years; FDA added its results to the labelling in June 2023 (supplement S040). Its posted results report the mean change from baseline on the wrinkle assessment score (a fall means improvement), separately for lighter (Fitzpatrick I–III) and darker (IV–VI) skin types:
| Time after treatment | Nasolabial folds, I–III (504) | Nasolabial folds, IV–VI (271) | Cheek folds, I–III (128) | Cheek folds, IV–VI (29) |
|---|---|---|---|---|
| Month 6 | −1.73 | −1.82 | −1.54 | −1.88 |
| Month 13 | −1.74 | −1.70 | −1.49 | −1.96 |
| Year 2 | −1.60 | −1.63 | −1.47 | −1.89 |
| Year 3 | −1.16 | −1.25 | −1.30 | −1.74 |
| Year 4 | −0.80 | −0.95 | −0.93 | −1.38 |
| Year 5 | −0.47 | −0.62 | −0.62 | −1.08 |
Expressed as the share of the six-month improvement still present (our arithmetic from the posted means):
| Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|
| Nasolabial folds, I–III | 92% | 67% | 46% | 27% |
| Nasolabial folds, IV–VI | 90% | 69% | 52% | 34% |
| Cheek folds, I–III | 95% | 84% | 60% | 40% |
The shape is consistent across groups: the improvement holds roughly steady to about two years, then declines by a fairly even amount each year. That shape fits the two-year claim and also shows its limit — by year 4 less than half of the average nasolabial improvement remained. The study did not include an untreated group, so the decline combines any loss of treatment effect with five years of ordinary ageing, and it cannot separate the two. These are group averages; a mean change of −0.47 says nothing about how any single face looked. The cheek-fold group with darker skin is small (29), so its figures are less certain than the others.
The same study also counted lumps. Over five years, 30.5% of participants with skin types I–III and 24.8% with types IV–VI had at least one injection-site nodule or papule recorded. How nodules are classified and handled is set out on our Sculptra page; that page also carries FDA's device-report counts.
What other studies add
The 2009 nasolabial-fold trial reported improvement “at all time points” up to 25 months after the last treatment in the Sculptra group, and called the correction “long-lasting (up to 25 months)” (Narins 2010); its authors note the participants were mostly white women with skin types II and III. For a direct comparison with a hyaluronic-acid filler over 120 weeks, see our Sculptra vs filler page, and for how Sculptra compares with calcium hydroxylapatite, Sculptra vs Radiesse. Durations quoted for body areas such as the buttocks come from much smaller, uncontrolled studies, set out on our buttocks page.
What the record does not show
It does not show how long Sculptra lasts after retreatment, because the five-year study gave one course. It does not show results beyond five years. It does not separate the treatment's fading from ageing after year 1, because no untreated group was followed that long. And it does not tell any individual how long their result would last — the trials report averages and responder rates. It does show, more precisely than the brochure, that “up to two years” is roughly where the average improvement starts to decline, not where it ends. What sessions cost is on our Sculptra cost page.
Sources and dates
Opened 14 October 2026: ClinicalTrials.gov results for NCT02425943 (post-approval study), NCT04595331 (extension) and NCT04124692 (cheek trial); openFDA PMA record P030050 supplement S040; PubMed record 20159311 (Narins 2010); Galderma's US Sculptra site and its footnotes. Percentages remaining are our arithmetic from the posted means. Corrections go to the contact page.